2086689-87-2

Basic information

• Product Name: C₁₃H₂₁NO₂
• CAS NO: 2086689-87-2
• Molecular Weight: 223.315
• Mol File: 2086689-87-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 266.8±40.0 °C(Predicted)
• Density: 1.01±0.1 g/cm3(Predicted)
• CAS DataBase Reference: C₁₃H₂₁NO₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₃H₂₁NO₂(2086689-87-2)
• EPA Substance Registry System: C₁₃H₂₁NO₂(2086689-87-2)

Safety Data

• Hazardous Substances Data: 2086689-87-2(Hazardous Substances Data)

Upstream product

• 5891-21-4 5-chloro-2-pentanone 
• 75-20-7 calcium carbide 
• 27532-96-3 glycine tert-butyl ester hydrochloride 
• 872-32-2 2-methyl-1H-pyrroline 
• 5292-43-3 bromoacetic acid tert-butyl ester 

Downstream Products

• 1446261-44-4 (10aR)-2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one 
• 1446261-61-5 (R)-methyl 9-fluoro-11b-methyl-6-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole-7-carboxylate 

Relevant articles and documents

TREATMENT CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS, TEMOZOLOMIDE AND/OR RADIATION THERAPY

Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and/or radiation therapy. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and the use thereof.

CRYSTALLINE FORMS OF SALTS OF FUSED TERA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARAZOLONES, AND USES THEREOF

Disclosed herein are salts of (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, and crystalline forms (polymorphs) thereof. Also disclosed herein are methods of preparing those crystalline forms, and methods of using at least one of those crystalline forms in treating a cancer responsive to inhibition of PARP, especially a cancer associated with BRCA1/2 mutant activities or other HR deficiencies, in a subject.